As estimated worldwide in 2011, the number of peoples with diabetes were around 346 million and its number is unceasingly getting bigger. It is expected to be double in number by 2030. Diabetic retinopathy and diabetic macular edema is occurring, which leads to the vision loss. These adverse conditions mostly occur in patient having high blood sugar level and high blood pressure. Therefore, the consequential increase in growth of diabetic macular edema therapeutics pipeline is observed.
Diabetic macular edema became the foremost cause of vision loss in diabetic patients and working-aged adults. Diabetic macular edema is generally a building up of fluid in macula region in retina, which is present at the back of the eye and responsible for making sharp and straight-headed vision with macula. Swelling and thickening of macula majorly affecting vision by distorting it. The accumulation of fluid causes the leakage which can damage the blood vessels present near retina. The foremost cause of diabetic macular edema is diabetic retinopathy, but in some cases, it can subsequently occur after an eye surgery. It is also found that inflammation in eye can cause diabetic macular edema. Theprimary symptoms of diabetic macular edema is the wavy or blurred vision, in which colour may be faded. If it occurs to only one eye, the blurry vision will not be noticed until the condition become severe.
Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/diabetic-macular-edema-therapeutics-pipeline-analysis/toc-sample
In March 2016, F Hoffmann-La Roche AG, Inc. started a Phase II clinical study on drug RO6867461, in participants with center-involving Diabetic macular edema. In November 2016, Regeneron Pharmaceuticals, Inc. started a Phase IIIb of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with Diabetic Macular Edema.
Some of the companies having a pipeline of diabetic macular edema therapeutics include Regeneron Pharmaceuticals, Inc., Bayer AG, Allergan, Clearside Biomedical, Inc., Novartis AG, Chengdu Kanghong Biotech Co., Ltd., ThromboGenics NV, F Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Valeant Pharmaceuticals International, Inc.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)